环核苷酸磷酸二酯酶3/4抑制剂在慢性阻塞性肺疾病中的研究前景
[Research prospect of cyclic nucleotide phosphodiesterase 3/4 inhibitors in chronic obstructive pulmonary disease].
作者信息
Wang Z H, Wu F, Deng Z S, Dai C Q, Cai G N, Zhou Y M
机构信息
National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Respiratory and Critical Care Medicine, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Guangzhou National Laboratory, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Respiratory and Critical Care Medicine, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510000, China.
出版信息
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Sep 12;47(9):876-884. doi: 10.3760/cma.j.cn112147-20240408-00188.
Current treatments for chronic obstructive pulmonary disease (COPD) are relatively limited and cannot meet the needs of all patients. Ensifentrine (development code RPL554), a representative drug of cyclic nucleotide phosphodiesterase 3/4 (PDE 3/4) inhibitors, has shown promising developments in the treatment of COPD in recent years, which need to be summarized. This article reviews the mechanism and clinical research progress of ensifentrine, focusing on its chemical structure, pharmacokinetics, pathophysiological mechanism, efficacy, and safety. Additionally, we provide clinical application suggestions and future research prospects.
慢性阻塞性肺疾病（COPD）的现有治疗方法相对有限，无法满足所有患者的需求。恩昔芬净（研发代码RPL554）是环核苷酸磷酸二酯酶3/4（PDE 3/4）抑制剂的代表性药物，近年来在COPD治疗方面展现出了良好的进展，有必要进行总结。本文综述了恩昔芬净的作用机制及临床研究进展，重点关注其化学结构、药代动力学、病理生理机制、疗效和安全性。此外，我们还提供了临床应用建议和未来研究前景。
Zotero 插件